DHEA for Women Over 40: Evidence, Adrenal Decline, and What to Know Before Discussing It With a Provider

DHEA for women is one of the most overlooked topics in hormone health. It is the most abundant steroid hormone in the human body. It sits directly upstream of both estrogen and testosterone. And yet its levels decline by roughly 80 percent between the ages of 25 and 70. Despite this, DHEA for women rarely comes up in standard hormonal evaluations. It is frequently dismissed as a supplement with inconsistent evidence. And it is almost never discussed when women in their 40s and 50s describe fatigue, low libido, or mood changes that may be connected to its decline. For a detailed overview of how adrenal androgens change with age, the NIH Endotext chapter on Adrenal Androgens and Aging provides comprehensive background.

The full picture is more nuanced than a simple dismissal. In some areas, the research on DHEA for women is genuinely strong. Vaginal DHEA, for example, has FDA approval for a specific postmenopausal indication. In other areas, the evidence is mixed and requires a careful individual evaluation. Moreover, DHEA occupies a unique regulatory position: it is legally sold over the counter as a supplement, yet it is also available as a pharmaceutical-grade compounded preparation with provider oversight. This guide covers all of it clearly, so you can bring an informed question to a licensed specialist.

What DHEA for Women Actually Is and Why It Matters

DHEA, or dehydroepiandrosterone, is a steroid prohormone produced primarily by the zona reticularis of the adrenal cortex in response to ACTH, with smaller contributions from the ovarian theca cells and the brain. It circulates primarily as DHEA-sulfate (DHEA-S), which is its more stable, measurable form in the bloodstream and the value reported on standard lab panels.

DHEA is the most abundant circulating steroid in the body and functions as a direct precursor to both androgens and estrogens. After menopause, when the ovaries stop producing significant amounts of estrogen and testosterone directly, peripheral conversion of DHEA becomes the primary source of sex steroid hormones in women. Research suggests that in postmenopausal women, 100% of circulating estrogens are derived from DHEA conversion in peripheral tissues including skin, adipose tissue, breast, and brain. The NIH Endotext chapter on Adrenal Androgens and Aging covers this pathway in depth. This makes the adrenal DHEA axis specifically important to understand in the context of menopause and perimenopause, where it represents the body’s main remaining endocrine manufacturing pathway for sex steroids.

Adrenopause: The Decline Nobody Talks About

The progressive, age-related decline in adrenal androgen production has a name: adrenopause. Unlike menopause, it has no discrete onset and no identifiable transition point. It begins quietly in the late 20s and continues for the rest of life, with the steepest rate of decline occurring between the 30s and 60s. By age 70, circulating DHEA-S levels are typically 80 percent lower than at their peak.

Adrenopause affects men and women alike, but the consequences are arguably more significant for women, precisely because the ovaries eventually stop producing their own sex steroids and the adrenal-derived DHEA pathway becomes the primary source. A 65-year-old woman’s estrogen and testosterone levels are heavily influenced by how much DHEA her adrenal glands are still producing and how efficiently peripheral tissues are converting it.

The symptoms associated with adrenal androgen decline are not neatly distinct from those of ovarian hormone decline. They overlap substantially: fatigue, reduced libido, mood changes, and diminished sense of wellbeing are common to both. This overlap is one reason DHEA for women remains an underexplored component of comprehensive hormone evaluation, even though DHEA-S is a simple, inexpensive, and informative addition to any hormone panel.

What the Research Shows About DHEA for Women

The evidence base for DHEA in women is large, somewhat heterogeneous, and best understood by distinguishing between route of administration and specific outcomes. Conflating oral systemic DHEA with vaginal DHEA leads to confusion because the two have meaningfully different evidence profiles.

Vaginal DHEA: Strongest Evidence

The most consistent and clinically validated evidence for DHEA in women relates to vaginal administration for genitourinary syndrome of menopause (GSM). A systematic review published in the International Journal of Molecular Sciences in 2025 concluded that vaginal DHEA therapy was more effective than systemic oral DHEA in perimenopausal and postmenopausal women for outcomes including sexual interest, lubrication, pain, arousal, orgasm, and sexual frequency. The FDA reached the same conclusion when it approved Intrarosa (prasterone 6.5 mg vaginal insert) in 2016 for the treatment of moderate to severe dyspareunia in postmenopausal women. Prasterone is the INN name for DHEA, and Intrarosa is the only FDA-approved DHEA product.

The reason vaginal DHEA outperforms oral DHEA for genitourinary outcomes is primarily pharmacological: local administration delivers DHEA directly to the vaginal tissue where it is converted to estrogen and androgen intracellularly. This allows for meaningful local hormonal activity with minimal systemic absorption, which has favorable implications for women who cannot or do not want systemic hormone exposure.

Systemic Oral DHEA: Mixed but Evolving Evidence

For systemic oral DHEA, the evidence landscape is more complex. A 2025 meta-analysis published in Diabetology and Metabolic Syndrome examined 21 randomized controlled trials and found that DHEA supplementation significantly increased both estradiol levels (weighted mean difference of 7.86 pg/mL) and testosterone levels (WMD of 24.31 ng/dL) in postmenopausal women. The hormonal effect of oral DHEA is therefore well-established. Where the evidence is less clear is in translating those hormone level increases into consistent, measurable clinical benefits for specific outcomes.

A review published in PubMed examining oral DHEA for libido and wellbeing in women concluded that results from randomized controlled trials are inconsistent, limited by small sample sizes and short treatment durations. The studies showing benefit tend to involve women with documented low DHEA-S levels, women with adrenal insufficiency, or women who receive adequate baseline evaluation. The studies showing less consistent benefit tend to be in mixed populations without baseline DHEA-S confirmation of deficiency.

This pattern is clinically important. The question is not “does DHEA work for all women over 40” but rather “does DHEA supplementation produce clinical benefit in women who have documented low DHEA-S and symptoms plausibly connected to that deficiency.” That is a different question, and the answer is more favorable.

DHEA for Women: Regulatory Status Explained

DHEA occupies an unusual regulatory position in the United States. Understanding it prevents confusion between genuinely different products that share a name.

Over-the-counter DHEA supplements are classified as dietary supplements and are regulated under DSHEA (Dietary Supplement Health and Education Act of 1994) rather than as drugs. They are widely available, legally sold without a prescription, and do not require FDA approval for safety or efficacy before going to market. The quality, purity, and actual DHEA content of OTC supplements varies considerably between manufacturers, and independent testing has found significant discrepancies between labeled and actual DHEA content in commercial products.

Intrarosa (prasterone 6.5 mg vaginal insert) is the only FDA-approved DHEA product. It was approved in 2016 for the treatment of moderate to severe dyspareunia associated with vulvar and vaginal atrophy due to menopause. It is dispensed as a prescription pharmaceutical product with quality controls and manufacturing standards that OTC supplements do not carry.

Compounded DHEA is available from licensed 503A compounding pharmacies under a valid physician prescription. Compounded preparations allow for custom dosing (typically 5 to 50 mg oral capsules or custom topical preparations) and provide pharmaceutical-grade quality assurance that OTC supplements do not guarantee. This is generally the preferred route for women exploring DHEA as part of a medically supervised hormone optimization protocol, because a licensed provider can order the appropriate lab testing, confirm the clinical rationale, document baseline values, and monitor response.

Who Benefits from DHEA for Women: What Providers Look For

DHEA for women is most clinically grounded in the following situations, all of which require a provider evaluation rather than self-supplementation:

• Documented low DHEA-S on a baseline hormone panel, combined with symptoms plausibly connected to adrenal androgen decline, such as fatigue, reduced libido, mood changes, or reduced sense of wellbeing
• Postmenopausal women experiencing genitourinary symptoms including vaginal dryness, pain with intercourse, or urinary changes, where local vaginal DHEA may be appropriate with or without systemic HRT
• Women in perimenopause with a complete hormone panel showing low or low-normal DHEA-S alongside other hormonal shifts, where DHEA is being considered as one component of a broader hormone optimization evaluation
• Women with adrenal insufficiency, where clinical guidelines from the Endocrine Society suggest DHEA replacement may be considered in those with low energy or libido despite otherwise optimal management

The baseline evaluation for DHEA always includes DHEA-S, and typically also includes a full hormone panel covering estradiol, progesterone, total and free testosterone, SHBG, FSH, LH, and thyroid function. This allows a provider to understand the full hormonal picture rather than treating a single isolated marker. The companion article on What Labs Do You Need Before Starting Hormone Therapy covers the complete evaluation in detail.

Safety Profile: What Women Using DHEA Should Know

At physiological doses used in clinical practice (typically 5 to 50 mg oral daily, or 6.5 mg vaginal), DHEA for women has a generally favorable tolerability profile. Side effects at standard doses are typically mild. At higher doses or in women with already-normal DHEA-S and testosterone levels, androgenic effects including acne, oily skin, and unwanted hair growth become more possible. This is one reason baseline testing matters: knowing where a patient’s androgen levels start informs the appropriate dose and reduces the risk of overshooting.

DHEA’s conversion to estrogen is also relevant for women with a history of hormone-sensitive conditions. While Intrarosa’s minimal systemic absorption profile makes it appropriate even for some breast cancer survivors per certain clinical guidelines, systemic oral DHEA raises the same considerations as any hormone that increases circulating estrogen, and personal and family health history should be part of the evaluation. A thorough provider assessment before initiating any DHEA protocol is not optional. For women already on HRT and exploring how DHEA fits alongside existing estrogen and progesterone therapy, the article on Beyond Hormone Replacement: How Peptide Therapy Enhances HRT covers the intersection of layered hormone approaches. For women also interested in the broader landscape of women’s hormone optimization, the guide to menopause and hormone therapy provides essential context.